Fausto Castagnetti
"Seragnoli" Institute of Hematology Bologna (Italy) · Department of Hematology, S. Orsola-Malpighi University of Bologna
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fausto Castagnetti as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06409936 · PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto · recruiting · CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive · principal investigator
- Ph2NCT02810990 · Bosutinib in Elderly Chronic Myeloid LeukemiaGruppo Italiano Malattie EMatologiche dell'Adulto · completed · Chronic Myeloid Leukemia · study chair
- Ph2NCT02398825 · Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibGruppo Italiano Malattie EMatologiche dell'Adulto · terminated · Chronic Myeloid Leukemia, Chronic Phase, Adults · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:38 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- 295 citationsRCR 5.9
- 165 citationsRCR 4.1
- 156 citationsRCR 3.8
- Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.Haematologica · 2007144 citationsRCR 2.9
- 90 citationsRCR 2.6
- Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Leukemia · 201582 citationsRCR 2.6
- Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.Haematologica · 200878 citationsRCR 1.7
- Differences among young adults, adults and elderly chronic myeloid leukemia patients.Ann Oncol · 201578 citationsRCR 2.9
- Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.Blood · 200475 citationsRCR 1.5
- 58 citationsRCR 1.4